Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Squamous Non-Small Cell Lung Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Squamous Non-Small Cell Lung...

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Head And Neck Squamous...

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Peritoneal Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Peritoneal Cancer. According to...

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Metastatic Ovarian Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Metastatic Ovarian Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Metastatic Ovarian Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Small Cell Lung Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Small Cell Lung Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Non-Small Cell Lung Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Solid Tumor: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Solid Tumor. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Solid Tumor

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Sarcomas: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Sarcomas. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Sarcomas

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Metastatic Melanoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Metastatic Melanoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Metastatic Melanoma

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Small-Cell Lung Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Small-Cell Lung Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Small-Cell Lung Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Metastatic Hepatocellular Carcinoma (HCC): Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Metastatic Hepatocellular Carcinoma (HCC)....

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Metastatic Hepatocellular Carcinoma (HCC)

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hepatocellular Carcinoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hepatocellular Carcinoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Hepatocellular Carcinoma

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Metastatic Breast Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Metastatic Breast Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Metastatic Breast Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Head And Neck Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Head And Neck Cancer....

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Head And Neck Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma): Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Hodgkin Lymphoma (B-Cell Hodgkin...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma)

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Non-Hodgkin Lymphoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Non-Hodgkin Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Non-Hodgkin Lymphoma

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Melanoma: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Melanoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Melanoma

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Cervical Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Cervical Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Cervical Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Ovarian Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Ovarian Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Ovarian Cancer

Data Insights

SGN-1 by Guangzhou Huajin Pharmaceutical Technology for Breast Cancer: Likelihood of Approval

SGN-1 is under clinical development by Guangzhou Huajin Pharmaceutical Technology and currently in Phase II for Breast Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - SGN-1 in Breast Cancer